Knowledge, Perceptions, and Self-Reported Rates of Influenza Immunization among Canadians at High Risk from Influenza: A Cross-Sectional Survey.

adults 18–64 years adults ≥ 65 years of age chronic medical conditions influenza vaccination vaccination coverage

Journal

Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355

Informations de publication

Date de publication:
17 Aug 2023
Historique:
received: 16 06 2023
revised: 10 08 2023
accepted: 16 08 2023
medline: 26 8 2023
pubmed: 26 8 2023
entrez: 26 8 2023
Statut: epublish

Résumé

The Public Health Agency of Canada recommends that 80% of high-risk persons, including adults aged ≥65 years and 18-64 years with certain comorbidities, be vaccinated against influenza. During the 2022-2023 influenza season, we conducted an online survey of 3000 Canadian residents aged ≥18 years randomly recruited from the Léger Opinion (LEO) consumer panel to assess knowledge and perceptions about influenza vaccination as well as survey self-reported vaccination rates. Overall, 47.3% received an influenza vaccination during the 2022-2023 season. Vaccination rates among persons aged 18-64 years with high-risk medical conditions (n = 686) and among adults aged ≥65 years (n = 708) were 46.4% and 77.4%, respectively; 77.8% and 88.5%, respectively, believed influenza vaccination was important for people at high risk from influenza. Only 35.8% of adults aged 18-64 years with comorbidities were aware of being at high risk; 66.0% of this group was vaccinated against influenza, compared with 37.0% of those unaware of being at high-risk. During 2022-2023, 51.3% of people aged ≥65 years and 43.0% of people aged 18-64 years with comorbidities discussed influenza vaccination with healthcare providers. These findings suggest gaps in education regarding the importance of influenza vaccination among people at risk of influenza complications.

Identifiants

pubmed: 37631946
pii: vaccines11081378
doi: 10.3390/vaccines11081378
pmc: PMC10459598
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : CSL Seqirus Inc.
ID : NA

Références

Influenza Other Respir Viruses. 2018 Mar;12(2):232-240
pubmed: 29125689
Health Promot Chronic Dis Prev Can. 2023 Feb;43(2):87-97
pubmed: 36794825
MMWR Recomm Rep. 2022 Aug 26;71(1):1-28
pubmed: 36006864
Lancet Infect Dis. 2010 Feb;10(2):83-92
pubmed: 20113977
Rev Med Virol. 2021 Jul;31(4):e2188
pubmed: 33128859
JAMA Netw Open. 2022 Apr 1;5(4):e228873
pubmed: 35486404
Vaccine. 2022 Jan 24;40(3):503-511
pubmed: 34916102
Clin Infect Dis. 2019 Nov 13;69(11):1845-1853
pubmed: 30715278
J Am Heart Assoc. 2021 Mar 16;10(6):e019636
pubmed: 33719496
Cell Immunol. 2020 Feb;348:103998
pubmed: 31733824

Auteurs

Paul Roumeliotis (P)

School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON K1N 6N5, Canada.

Sherilyn K D Houle (SKD)

School of Pharmacy, University of Waterloo, Waterloo, ON N2L 3G1, Canada.

Ajit Johal (A)

Travelrx and Immunize.io, Vancouver, BC V5Z 3Y1, Canada.

Bertrand Roy (B)

CSL Seqirus Inc., Kirkland, QC H9H 4M7, Canada.

Wendy Boivin (W)

CSL Seqirus Inc., Kirkland, QC H9H 4M7, Canada.

Classifications MeSH